Proximo Medical announced a partnership with Acarix, a Swedish medical device company that provides innovative solutions for rapid AI-based rule out of Coronary Artery Disease (CAD).

The CADScor® System technology uses AI and a smart sensor to rule out CAD in patients experiencing symptoms of suspected CAD. It is a non-invasive assessment and provides results to heath care professionals and patients in less than 10 minutes.

With 9 out 10 patients undergoing CAD diagnostic testing not having CAD, the CADScor® System has significant potential in reducing millions of unnecessary, invasive, and costly diagnostic procedures and giving patients peace of mind. The CADScor® System received FDA De Novo clearance in 2020, and a CPT III code approval by AMA in October 2021.

“By partnering with Proximo Medical, we rapidly initiate the commercialization of the CADScor system in the U.S., immediately gaining market access and an experienced cardiovascular sales force with expertise in launching innovations in cardiovascular technology,” states Per Persson, CEO, Acarix.

“Coronary Artery Disease is a major burden on the U.S. healthcare system, and the diagnostic pathways are costly and stressful for patients. The CADScor System is an innovative, ultrasensitive device designed to support a safe, reliable and affordable rule-out of significant CAD at early stages of the diagnostic pathway. Proximo is excited to bring this technology to select U.S. cities.” comments Gabe Szabo, CEO Proximo Medical.

Leave a Reply

Your email address will not be published. Required fields are marked *